Literature DB >> 7609169

Primary nocturnal enuresis: a comparison among observation, imipramine, desmopressin acetate and bed-wetting alarm systems.

J M Monda1, D A Husmann.   

Abstract

Patients with primary nocturnal enuresis were entered into 4 treatment groups: observation, imipramine, desmopressin acetate or alarm therapy. Patients were weaned from therapy 6 months after inclusion in the study and were evaluated for continence at 3, 6, 9 and 12 months after beginning the study protocol. Of the 50 patients under observation 6% were continent at 6 months and 16% were continent within 12 months. Of 44 patients treated with imipramine 36% were continent at 6 months on medication; however, only 16% were continent at 12 months, off medication. Similarly, of the 88 patients treated with desmopressin acetate 68% were continent at 6 months but only 10% were continent at 12 months. Of the 79 patients treated with alarm therapy 63% were continent at 6 months and 56% were dry at 12 months. Although each form of therapy improved continence over observation alone (p < 0.01), only the bed-wetting alarm system demonstrated persistent effectiveness (p < 0.001).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7609169

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

1.  Efficacy and safety of nasal desmopressin in the long-term treatment of primary nocturnal enuresis.

Authors:  Kenichi Kano; Osamu Arisaka
Journal:  Pediatr Nephrol       Date:  2006-05-25       Impact factor: 3.714

2.  The role of urine osmolality and ions in the pathogenesis of primary enuresis nocturna and in the prediction of responses to desmopressin and conditioning therapies.

Authors:  Tolga Unüvar; Ferah Sönmez
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Topical use of Matricaria recutita L (Chamomile) Oil in the Treatment of Monosymptomatic Enuresis in Children: A Double-Blind Randomized Controlled Trial.

Authors:  Hosein Sharifi; Mohammad Bagher Minaie; Mohammad Javad Qasemzadeh; Nematollah Ataei; Mohammad Gharehbeglou; Mojtaba Heydari
Journal:  J Evid Based Complementary Altern Med       Date:  2015-09-30

Review 4.  Contemporary and emerging drug treatments for urinary incontinence in children.

Authors:  Mitchell R Humphreys; Yuri E Reinberg
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

5.  The efficacy of the addition of short-term desmopressin to alarm therapy in the treatment of primary nocturnal enuresis.

Authors:  Cuneyt Ozden; Ozdem Levent Ozdal; Binhan Kagan Aktas; Alper Ozelci; Serkan Altinova; Ali Memis
Journal:  Int Urol Nephrol       Date:  2008-03-05       Impact factor: 2.370

Review 6.  Tricyclic and related drugs for nocturnal enuresis in children.

Authors:  Patrina H Y Caldwell; Premala Sureshkumar; Wicky C F Wong
Journal:  Cochrane Database Syst Rev       Date:  2016-01-20

7.  Effect of desmopressin lyophilisate (MELT) plus anticholinergics combination on functional bladder capacity and therapeutic outcome as the first-line treatment for primary monosymptomatic nocturnal enuresis: A randomized clinical trial.

Authors:  Myungsun Shim; Woo Jin Bang; Cheol Young Oh; Min Jae Kang; Jin Seon Cho
Journal:  Investig Clin Urol       Date:  2021-03-16

8.  Alarm interventions for nocturnal enuresis in children.

Authors:  Patrina Hy Caldwell; Miriam Codarini; Fiona Stewart; Deirdre Hahn; Premala Sureshkumar
Journal:  Cochrane Database Syst Rev       Date:  2020-05-04

9.  Efficacy of an enuresis alarm, desmopressin, and combination therapy in the treatment of saudi children with primary monosymptomatic nocturnal enuresis.

Authors:  Abul-Fotouh Abdel-Maguid Ahmed; Moamen Mohammed Amin; Mahmoud Mohammed Ali; Essam Abdel-Moneim Shalaby
Journal:  Korean J Urol       Date:  2013-11-06

10.  Pediatric acupuncture: a review of clinical research.

Authors:  Jeffrey I Gold; Colette D Nicolaou; Katharine A Belmont; Aaron R Katz; Daniel M Benaron; Wendy Yu
Journal:  Evid Based Complement Alternat Med       Date:  2008-01-10       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.